PUBLISHER: Grand View Research | PRODUCT CODE: 1631183
PUBLISHER: Grand View Research | PRODUCT CODE: 1631183
The global electronic drug delivery systems market size is expected to reach USD 20.19 billion by 2030, registering a CAGR of 9.2% from 2025 to 2030, according to a new report by Grand View Research, Inc. Technological advancements allowing easy self-administration technologies, mainly in infusion pumps and auto injectors that help in large-volume and high-viscosity biologic drugs have created a potential market opportunity for the companies. Approvals of novel drug formulations for use in infusion pumps allow a novel treatment option, thereby advancing diabetes care in adults.
In October 2019, Novo Nordisk received the U.S. Food and Drug Administration approval for Fiasp, insulin injection for use in insulin pumps for patients with type 1 and 2 diabetes. Moreover, the innovative wearable infusion pumps allow the patients to wirelessly connect to smartphone apps. This enables healthcare professionals to track patient data and tailor specific therapies as per individual requirements. The aforementioned factors have augmented the demand for electronic drug delivery systems globally. However, automated pumps may have risks of wrong dosage with technical glitches and might lead to adverse drug reactions. This may hinder the market growth.